Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Xenetic and Santersus enter into definitive share exchange agreement

Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected...

September 17, 2026

Developments

BioPorto initiates patient enrollment in adult urine NGAL validation study

BioPorto (CPH: BIOPOR) has announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to...

September 17, 2026

Developments

Firefly’s Evoke platform selected for Radial’s AI-native brain medicine operating system

Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic collaboration with closely held Radial, operator of the U.S.’s largest network of brain medicine clinics, to pursue the integration of Firefly’s...

September 17, 2026

Developments

FDA grants Armata Breakthrough Therapy designation for AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate, for...

September 14, 2026

Developments

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced a clinical trial collaboration agreement with Merck (NYSE: MRK) to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda...

September 14, 2026

Developments

Eloxx announces first patients dosed in study of exaluren in NMAS

Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). According to...

September 11, 2026

Developments

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of the first patients with alcohol use disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the company’s proprietary psychedelic-based...

September 11, 2026

Developments

IMUNON enters CRADA with NCI to advance gene-based immunotherapy

IMUNON (NASDAQ: IMNN) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to support further clinical and non-clinical development of IMNN-001, the...

September 10, 2026

Developments

MolDX issues Bionano proposed LCD

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics (NASDAQ: BNGO) has announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors...

September 10, 2026

Developments

Ocumetics initiates patient recruitment for next-gen lens study

Ocumetics Technology (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the company’s ongoing human clinical...

September 8, 2026

Developments

eXoZymes selects Curia as CDMO for NCT

eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N...

September 8, 2026

Developments

Polyrizon completes site contracts for NASARIX first-in-human allergy study

Polyrizon (NASDAQ: PLRZ) has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. The planned first...

September 2, 2026

Developments

cbdMD to acquire Twinlab brands

cbdMD (NYSE American: YCBD) has announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea...

September 2, 2026

Developments

USPTO issues NOA for Purple’s next-gen multispecific antibody platform

Purple Biotech (NASDAQ/TASE: PPBT) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering tri-specific antibody constructs and methods of use...

September 2, 2026

Developments

Karyopharm submits sNDA for XPOVIO + ruxolitinib in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking accelerated approval for XPOVIO (selinexor) in combination with ruxolitinib for...

August 31, 2026

Developments

TELA announces COO/CFO transition and cost reduction

TELA Bio (NASDAQ: TELA) has announced that Roberto Cuca, chief operating officer and chief financial officer (COO/CFO), will step down from the role effective today. In a statement, Heather Getz, CEO of TELA, commented...

August 31, 2026

Developments

Aprea announces IP expansion for precision oncology programs

Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs. According to Aprea, the company has strengthened its global IP portfolio with 28...

August 28, 2026

Developments

Quoin reports positive interim data from study of topical treatment for NS

Quoin Pharmaceuticals (NASDAQ: QNRX) has announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome (NS), a rare, genetic skin disease...

August 28, 2026

Developments

BrainsWay Deep TMS study shows 70% reduction in suicidal ideation in MDD

BrainsWay (NASDAQ: BWAY; TASE: BWAY) has announced the publication of new peer-reviewed data in the Journal of Affective Disorders demonstrating significant reductions in suicidal ideation among patients with major...

August 27, 2026

Developments

Precision doses first patient in study of in vivo gene editing program in DMD

Precision Biosciences (NASDAQ: DTIL) has announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating its in vivo gene editing program, PBGENE-DMD, for the treatment of...

August 25, 2026

Developments

RMTG’s Cellgenic launches NK cell product line outside U.S.

Regenerative Medical Technology Group (RMTG) (OTCID: RMTG) has announced that its Cellgenic division has launched a natural killer (NK) cell product line for permitted markets outside the U.S., with an initial...

August 25, 2026

Developments

VERAXA and Secarna report positive results from AOC research collaboration

VERAXA Biotech (NASDAQ: VRXA) and closely held Secarna Pharmaceuticals have announced positive initial results from their research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for...

August 25, 2026

Subscribe